

Supplemental Table 1. The 50 top-cited articles ranked by citation numbers.

Rank	Article	Citation count
1	Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. <i>J Nucl Med.</i> 2009;50 Suppl 1:122S-150S	1407
2	Investigators P. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). <i>JAMA.</i> 1990;263(20):2753-2759	1366
3	Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. <i>N Engl J Med.</i> 1986;314(14):884-888	1129
4	Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. <i>J Nucl Med.</i> 2000;41(8):1369-1379	1089
5	Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. <i>N Engl J Med.</i> 2003;348(25):2500-2507	947
6	Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. <i>N Engl J Med.</i> 2000;343(4):254-261	794
7	Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. <i>Radiology.</i> 2004;231(2):305-332	774
8	Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. <i>JAMA.</i> 2001;285(7):914-924	702
9	Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. <i>Eur J Nucl Med Mol Imaging.</i> 2010;37(1):181-200	702
10	Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. <i>J Nucl Med.</i> 1995;36(7):1238-1248	668
11	Edwards CL, Hayes RL. Tumor scanning with ⁶⁷ Ga citrate. <i>J Nucl Med.</i> 1969;10(2):103-105	650
12	Pavel DG, Zimmer M, Patterson VN. In vivo labeling of red blood cells with ^{99m} Tc: a new approach to blood pool visualization. <i>J Nucl Med.</i> 1977;18(3):305-308	629

- 13 Wackers FJ, Berman DS, Maddahi J, et al. Technetium-99m hexakis 2-methoxyisobutyl
isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to 585
thallium-201 for myocardial perfusion imaging. *J Nucl Med.* 1989;30(3):301-311
- 14 Gabriel M, Decristoforo C, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET in
neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. *J* 580
Nucl Med. 2007;48(4):508-518
- 15 Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: 559
physiologic and benign variants. *Radiographics.* 1999;19(1):61-77; quiz 150-151
- 16 Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F- 559
FDG PET in oncology. *J Nucl Med.* 2008;49(3):480-508
- 17 Hull RD, Hirsh J, Carter CJ, et al. Pulmonary angiography, ventilation lung scanning,
and venography for clinically suspected pulmonary embolism with abnormal perfusion 549
lung scan. *Ann Intern Med.* 1983;98(6):891-899
- 18 Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation
of dementia: Regional brain metabolism and long-term outcome. *JAMA.* 526
2001;286(17):2120-2127
- 19 Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A
tabulated summary of the FDG PET literature. *J Nucl Med.* 2001;42(5 Suppl):1S-93S. 515
- 20 Keyes JW, Jr. SUV: Standard uptake or silly useless value? *J Nucl Med.* 513
1995;36(10):1836-1839
- 21 van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission
tomography in the preoperative assessment of patients with suspected non-small-cell 512
lung cancer: the PLUS multicentre randomised trial. *Lancet.* 2002;359(9315):1388-1393
- 22 Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use
of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer 481
Institute Trials. *J Nucl Med.* 2006;47(6):1059-1066
- 23 Taillefer R, Boucher Y, Potvin C, Lambert R. Detection and localization of parathyroid
adenomas in patients with hyperparathyroidism using a single radionuclide imaging 480
procedure with technetium-99m-sestamibi (double-phase study). *J Nucl Med.*
1992;33(10):1801-1807.
- 24 Small GW, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive 467
impairment. *N Engl J Med.* 2006;355(25):2652-2663
- 25 McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission
tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in 465
human beings. *Lancet.* 1998;352(9138):1433-1437

- 26 Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. *Eur J Nucl Med Mol Imaging.* 2005;32(4):486-510 464
- 27 Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. *Radiology.* 1999;213(2):530-536. 455
- 28 Kuhl DE, Barrio JR, Huang SC, et al. Quantifying local cerebral blood flow by N-isopropyl-p-[123I]iodoamphetamine (IMP) tomography. *J Nucl Med.* 1982;23(3):196-203. 453
- 29 Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. *Radiology.* 1993;189(3):847-850 448
- 30 Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. *Ann Intern Med.* 2003;139(11):879-892 443
- 31 Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. *J Nucl Med.* 2006;47(2):287-297 439
- 32 Patz EF, Jr., Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. *Radiology.* 1993;188(2):487-490 437
- 33 Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. *J Nucl Med.* 2005;46(8):1342-1348 432
- 34 Farrer C, Franck N, Georgieff N, Frith CD, Decety J, Jeannerod M. Modulating the experience of agency: a positron emission tomography study. *Neuroimage.* 2003;18(2):324-333 427
- 35 Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. *J Nucl Med.* 2003;44(8):1200-1209 424
- 36 Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. *J Nucl Med.* 2001;42(9):1412-1417 423
- 37 Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. *Int J Radiat Oncol Biol Phys.* 1996;36(2):417-428. 414

38	Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. <i>J Nucl Med.</i> 2001;42(3):432-445	411
39	Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. <i>J Nucl Cardiol.</i> 2004;11(2):171-185	407
40	Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. <i>J Nucl Med.</i> 1998;39(6):990-995	401
41	Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. <i>Int J Radiat Oncol Biol Phys.</i> 1993;25(5):805-813	401
42	Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. <i>Radiology.</i> 1991;179(3):765-770	401
43	Krenning EP, Bakker WH, Kooij PP, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. <i>J Nucl Med.</i> 1992;33(5):652-658	397
44	Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. <i>Eur J Nucl Med Mol Imaging.</i> 2015;42(2):328-354	394
45	Friedland RP, Budinger TF, Ganz E, et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. <i>J Comput Assist Tomogr.</i> 1983;7(4):590-598	393
46	Garcia EV, Van Train K, Maddahi J, et al. Quantification of rotational thallium-201 myocardial tomography. <i>J Nucl Med.</i> 1985;26(1):17-26	390
47	Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68%)Ga-labelled PSMA ligand and (18%)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. <i>Eur J Nucl Med Mol Imaging.</i> 2014;41(1):11-20	387
48	Bradley J, Thorstad WL, Mutic S, et al. <u>Impact</u> of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. <i>Int J Radiat Oncol Biol Phys.</i> 2004;59(1):78-86	374
49	Hawkins PN, Lavender JP, Pepys MB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. <i>N Engl J Med.</i> 1990;323(8):508-513	371
50	Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid (68)Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. <i>J Nucl Med.</i> 2015;56(5):668-674	369

Supplemental Table 2. The 50 top Altmetric articles ranked by Altmetric Attention Scores

Rank	Article	Altmetric Attention Score
1	Magnussen RA, Binzel K, Zhang J, et al. ACL graft metabolic activity assessed by (18)FDG PET-MRI. <i>Knee</i> . 2017;24(4):792-797	2487
2	Amen DG, Trujillo M, Keator D, et al. Gender-Based Cerebral Perfusion Differences in 46,034 Functional Neuroimaging Scans. <i>J Alzheimers Dis</i> . 2017;60(2):605-614	681
3	Jones DT, Knopman DS, Graff-Radford J, et al. In vivo F-18-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. <i>Neurology</i> . 2018;90(11): E947	602
4	Smith C. Postmortem Autopsy-Confirmation of Antemortem [F-18] FDDNP-PET Scans in a Football Player with Chronic Traumatic Encephalopathy COMMENT. <i>Neurosurgery</i> . 2018;82(2):246-246	540
5	Armstrong AJ, Anand A, Edenbrandt L, et al. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer A Secondary Analysis of a Randomized Clinical Trial. <i>Jama Oncol</i> . 2018;4(7):944-951	519
6	Grootendorst MR, Cariati M, Pinder SE, et al. Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery Using F-18-FDG Cerenkov Luminescence Imaging: A First-in-Human Feasibility Study. <i>J Nucl Med</i> . 2017;58(6):891-898	508
7	James OG, Doraiswamy PM, Borges-Neto S. PET imaging of tau pathology in Alzheimer's disease and tauopathies. <i>Front Neurol</i> . 2015;6	494
8	Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. <i>Alzheimers Dement</i> . 2013;9(1): E1-E16	483
9	Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. <i>Alzheimers Dement</i> . 2018;14(8):989-997	479
10	Bateman TM. Cardiac sarcoidosis: An important niche for PET, but a journey just begun. <i>J Nucl Cardiol</i> . 2017;24(2):425-428	455
11	Sun YJ, Yu HJ, Ma JQ, Lu PO. The Role of F-18-FDG PET/CT Integrated Imaging in Distinguishing Malignant from Benign Pleural Effusion. <i>Plos One</i> . 2016;11(8)	450
12	Kanemura S, Kuribayashi K, Funaguchi N, et al. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to	437

	platinum-based doublet chemotherapy in malignant pleural mesothelioma. <i>Eur J Radiol.</i> 2017; 86:92-98	
13	Kitajima K, Doi H, Kuribayashi K, et al. Prognostic value of pretreatment volume-based quantitative (18)F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. <i>Eur J Radiol.</i> 2017; 86:176-183	437
14	Bateman TM, Dilsizian V, Beanlands RS, DePuey EG, Heller GV, Wolinsky DA. American Society of Nuclear Cardiology and Society of Nuclear Medicine and Molecular Imaging Joint Position Statement on the Clinical Indications for Myocardial Perfusion PET. <i>J Nucl Cardiol.</i> 2016;23(5):1227-1231	431
15	Tilkemeier PL, Bourque J, Doukky R, Sanghani R, Weinberg RL. ASNC imaging guidelines for nuclear cardiology procedures: Standardized reporting of nuclear cardiology procedures. <i>J Nucl Cardiol.</i> 2017;24(6):2064-2128	428
16	Troeltzsch M, Probst FA, Rominger A, et al. Comorbidity Assessment in Patients With Oral Squamous Cell Carcinoma: Can Imaging Techniques (Fludeoxyglucose Positron-Emission Tomographic Computed Tomography and Contrast-Enhanced Computed tomography) Provide Additional Information? <i>J Oral Maxil Surg.</i> 2018;76(1%):190-198	424
17	Chen ST, Siddarth P, Merrill DA, et al. FDDNP-PET Tau Brain Protein Binding Patterns in Military Personnel with Suspected Chronic Traumatic Encephalopathy. <i>J Alzheimers Dis.</i> 2018;65(1%):79-88	417
18	Bitencourt AGV, Lima ENP, Macedo BRC, Conrado JLFA, Marques EF, Chojniak R. Can positron emission mammography help to identify clinically significant breast cancer in women with suspicious calcifications on mammography? <i>Eur Radiol.</i> 2017;27(5%):1893-1900	404
19	Johnson P, Federico M, Kirkwood A, et al. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <i>New Engl J Med.</i> 2016;374(25):2419-2429	379
20	Stender J, Gosseries O, Bruno MA. Diagnostic precision of PET imaging and functional MRI in disorders of consciousness: a clinical validation study (vol 384, pg 514, 2014). <i>Lancet.</i> 2014;384(9942):494-494	366
21	Wey HY, Gilbert TM, Zurcher NR, et al. Insights into neuroepigenetics through human histone deacetylase PET imaging. <i>Sci Transl Med.</i> 2016;8(351)	349
22	Bloomfield PS, Selvaraj S, Veronese M, et al. Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [C-11]PBR28 PET Brain Imaging Study. <i>Am J Psychiat.</i> 2016;173(1):44-52	340
23	Nakatomi Y, Mizuno K, Ishii A, et al. Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An C-11-(R%)-PK11195 PET Study. <i>J Nucl Med.</i> 2014;55(6%):945-950	339

	Blakkisrud J, Londalen A, Martinsen ACT, et al. Tumor-Absorbed Dose for Non-Hodgkin	
24	Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate Lu-177-Lilotomab Satetraxetan. <i>J Nucl Med.</i> 2017;58(1):48-54	321
	Healy MA, Yin HY, Reddy RM, Wong SL. Use of Positron Emission Tomography to	
25	Detect Recurrence and Associations with Survival in Patients With Lung and Esophageal Cancers. <i>Jnci-J Natl Cancer I.</i> 2016;108(7)	320
	Mehanna H, Wong WL, McConkey CC, et al. PET-CT Surveillance versus Neck	
26	Dissection in Advanced Head and Neck Cancer. <i>New Engl J Med.</i> 2016;374(15):1444-1454	271
	Chen MK, Mecca AP, Naganawa M, et al. Assessing Synaptic Density in Alzheimer	
27	Disease with Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. <i>Jama Neurol.</i> 2018;75(10):1215-1224	246
	Scholl M, Lockhart SN, Schonhaut DR, et al. PET Imaging of Tau Deposition in the	
28	Aging Human Brain. <i>Neuron.</i> 2016;89(5):971-982	245
	Greenwood JP, Ripley DP, Berry C, et al. Effect of Care Guided by Cardiovascular	
29	Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates The CE-MARC 2 Randomized Clinical Trial. <i>Jama-J Am Med Assoc.</i> 2016;316(10):1051-1060	226
	Grove N, Zheng M, Bristow RE, Eskander RN. Extensive Tattoos Mimicking Lymphatic	
30	Metastasis on Positron Emission Tomography Scan in a Patient with Cervical Cancer. <i>Obstet Gynecol.</i> 2015;126(1):182-185	223
	Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in	
31	patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncol.</i> 2018;19(6):825-833	212
	Ramanan VK, Risacher SL, Nho K, et al. GWAS of longitudinal amyloid accumulation	
32	on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. <i>Brain.</i> 2015;138(Pt 10):3076-3088	187
	Kramer SD, Betzel T, Mu LJ, et al. Evaluation of C-11-Me-NB1 as a Potential PET	
33	Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk. <i>J Nucl Med.</i> 2018;59(4):698-703	179
	Sanches RF, Osorio FD, dos Santos RG, et al. Antidepressant Effects of a Single Dose	
34	of Ayahuasca in Patients with Recurrent Depression A SPECT Study. <i>J Clin Psychopharm.</i> 2016;36(1):77-81	171
	Frick A, Ahs F, Engman J, et al. Serotonin Synthesis and Reuptake in Social Anxiety	
35	Disorder A Positron Emission Tomography Study. <i>Jama Psychiat.</i> 2015;72(8):794-802	170
36	Palmqvist S, Zetterberg H, Mattsson N, et al. Detailed comparison of amyloid PET and	160

	CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> . 2015;85(14%):1240-1249	
37	Van Noorden R. Radioisotopes: The medical testing crisis. <i>Nature</i> . 2013;504(7479):202-204	158
38	Holmes SE, Hinz R, Conen S, et al. Elevated Translocator Protein in Anterior Cingulate in Major Depression and a Role for Inflammation in Suicidal Thinking: A Positron Emission Tomography Study. <i>Biol Psychiatry</i> . 2018;83(1):61-69	157
39	Savic I, Lindstrom P. PET and MRI show differences in cerebral asymmetry and functional connectivity between homo- and heterosexual subjects. <i>Proc Natl Acad Sci U S A</i> . 2008;105(27):9403-9408	157
40	Healy MA, Yin HY, Reddy RM, Wong SL. Use of Positron Emission Tomography to Detect Recurrence and Associations with Survival in Patients With Lung and Esophageal Cancers. <i>Jnci-J Natl Cancer I</i> . 2016;108(7)	153
41	Gerngross C, Schretter J, Klingenspor M, Schwaiger M, Fromme T. Active Brown Fat During F-18-FDG PET/CT Imaging Defines a Patient Group with Characteristic Traits and an Increased Probability of Brown Fat Redetection. <i>J Nucl Med</i> . 2017;58(7):1104-1110	151
42	Barrio JR, Small GW, Wong KP, et al. In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging (vol 112, E2039, 2015). <i>P Natl Acad Sci USA</i> . 2015;112(22): E2981-E2981	150
43	Greenwood JP, Herzog BA, Brown JM, et al. Prognostic Value of Cardiovascular Magnetic Resonance and Single-Photon Emission Computed Tomography in Suspected Coronary Heart Disease: Long-Term Follow-up of a Prospective, Diagnostic Accuracy Cohort Study. <i>Ann Intern Med</i> . 2016;165(1):1	145
44	Oberlin BG, Dziedzic M, Harezlak J, et al. Corticostriatal and Dopaminergic Response to Beer Flavor with Both fMRI and [C-11]raclopride Positron Emission Tomography. <i>Alcohol Clin Exp Res</i> . 2016;40(9)	143
45	Lohrke J, Siebeneicher H, Berger M, et al. (18)F-GP1, a Novel PET Tracer Designed for High-Sensitivity, Low-Background Detection of Thrombi. <i>J Nucl Med</i> . 2017;58(7):1094-1099	141
46	Joshi NV, Vesey AT, Williams MC, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. <i>Lancet</i> . 2014;383(9918):705-713	138
47	Papadakis GZ, Holland SM, Quezado M, Patronas NJ. Adrenal cryptococcosis in an immunosuppressed patient showing intensely increased metabolic activity on (18) F-FDG PET/CT. <i>Endocrine</i> . 2016;54(3):834-836	130

	Jauhar S, Nour MM, Veronese M, et al. A Test of the Transdiagnostic Dopamine	
48	Hypothesis of Psychosis Using Positron Emission Tomographic Imaging in Bipolar	127
	Affective Disorder and Schizophrenia. <i>Jama Psychiat.</i> 2017;74(12):1206-1213	
	Neumeister A, Normandin MD, Pietrzak RH, et al. Elevated brain cannabinoid CB1	
49	receptor availability in post-traumatic stress disorder: a positron emission tomography	126
	study. <i>Mol Psychiatr.</i> 2013;18(9):1034-1040	
	Karjalainen T, Karlsson HK, Lahnakoski JM, et al. Dissociable Roles of Cerebral mu-	
50	Opioid and Type 2 Dopamine Receptors in Vicarious Pain: A Combined PET-fMRI	123
	Study. <i>Cereb Cortex.</i> 2017;27(8):4257-4266	
